XTX Markets’s Sage Therapeutics SAGE Stock Holding History

XTX Markets’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,512	Closed	-$229K	–	180
2020 Q2	$229K	Buy	+5,512	New	+$200K	0.78%	65

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

XTX Markets's SAGE Position: Q3 2020 in Review

XTX Markets sold out of Sage Therapeutics (SAGE) in Q3 2020, closing a stake of 5,512 shares — an estimated $229K sold.

XTX Markets first reported a position in SAGE in Q2 2020 and held it in 1 quarter. The position peaked at $229K in Q2 2020. 231 funds tracked by Wall St. Rank hold SAGE as of Q3 2020.

XTX Markets reported no remaining Sage Therapeutics position as of Q3 2020 after selling out during the quarter.
XTX Markets sold 5,512 Sage Therapeutics shares in Q3 2020, an estimated $229K.
XTX Markets first reported a position in Sage Therapeutics in Q2 2020 and held it in 1 quarter.
XTX Markets's Sage Therapeutics position peaked at $229K in Q2 2020.
231 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2020.

Based on XTX Markets's 13F filing for Q3 2020, filed 29 Oct 2020.